Roche data at EAN 2021 showcase significant impact of neuroscience therapies

 -- Data for EVRYSDI reinforce safety profile and efficacy in a broad spinal

      muscular atrophy (SMA) population, following recent EU approval 
 
   -- Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) build 
      on safety profile and efficacy following recent CHMP opinion, including 
      in adults with concomitant autoimmune diseases (CAIDs) 
 
   -- OCREVUS data continue to show consistent benefit on slowing disease 
      progression in relapsing MS (RMS) and primary progressive MS (PPMS) 
 
   -- Additional presentations in Alzheimer's disease (AD), Huntington's 
      disease (HD) and Parkinson's disease (PD) continue to contribute to 
      understanding of these complex neurological disorders 

https://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Press-Release-nbsp-Roche-data-at-EAN-2021-showcase-significant-impact-of-therapies-across-diverse-35605052/